We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ariadne to Collaborate in €7.5M Neuromuscular Disease Consortium to Find Biomarkers
News

Ariadne to Collaborate in €7.5M Neuromuscular Disease Consortium to Find Biomarkers

Ariadne to Collaborate in €7.5M Neuromuscular Disease Consortium to Find Biomarkers
News

Ariadne to Collaborate in €7.5M Neuromuscular Disease Consortium to Find Biomarkers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ariadne to Collaborate in €7.5M Neuromuscular Disease Consortium to Find Biomarkers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ariadne announces a new collaboration with the BIO-NMD consortium led by Professor Alessandra Ferlini at the University of Ferrara, Italy. BIO-NMD is a three year EU-funded research project concentrating on the search for non-invasive biomarkers in people with Duchenne and Becker muscular dystrophies and Collagen VI myopathies.

The consortium, along with leading European academic and industry partners will work to identify non-invasive biomarkers for monitoring neuromuscular diseases (NMDs). Utilizing a myriad of OMIC sciences (genomic, transcriptomic, proteomic) and bioinformatics, the consortium hopes to bring qualified biomarkers for ongoing and further clinical trials.

Ariadne’s focus will be on providing bioinformatics tools for identifying functional pathways, potential targets and data outflow integration. The team will use its software, Pathway Studio®, as a core to integrate the data and information flow, in addition to using its expertise in information extraction to develop a literature-derived NMD biological knowledgebase of related processes and diseases. Specifically, Ariadne will build mechanistic models and pathways for NMD and interpret OMIC data generated by the consortium and partners in the context of NMD knowledgebase and networks.

BIO-NMD’s coordinator and chair of the steering committee, Professor Alessandra Ferlini (University of Ferrara, Italy) said, “The participation of Ariadne as partners together with INSERM is crucial for the project. Developing bioinformatic tools for OMIC studies analysis is essential and guarantees success to the project. In addition, it reinforces collaboration between academics and industries, again a key point for successful research to be translated into clinics.”

“We have always worked to establish strong collaborations with our clients”, says Gabriella Armin, Director of Marketing for Ariadne. “Given the importance of this project, we are proud to not only provide the technology to enable this type of innovative discovery research, but contribute scientifically as team members. Our technological expertise in knowledge enrichment continues to provide crucial bioinformatics tools for visualizing the complexity found in biology.”

The first update workshops for the BIO-NMD consortium are to be held in July in London and will include sessions dedicated to its industrial partners. The consortium will present and describe the project impacts, possible outcomes and identify links for future collaborations with industry.
Advertisement